CN105612159A - 二氮杂二环辛烷衍生物的结晶及其制备方法 - Google Patents

二氮杂二环辛烷衍生物的结晶及其制备方法 Download PDF

Info

Publication number
CN105612159A
CN105612159A CN201480055342.1A CN201480055342A CN105612159A CN 105612159 A CN105612159 A CN 105612159A CN 201480055342 A CN201480055342 A CN 201480055342A CN 105612159 A CN105612159 A CN 105612159A
Authority
CN
China
Prior art keywords
compound
vii
following formula
preparation
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480055342.1A
Other languages
English (en)
Chinese (zh)
Inventor
阿部隆夫
古内刚
坂卷仪晃
三桥那佳子
斋藤由美子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Pharma Co Ltd
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Priority to CN202010091853.6A priority Critical patent/CN111153903A/zh
Publication of CN105612159A publication Critical patent/CN105612159A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480055342.1A 2013-10-08 2014-10-08 二氮杂二环辛烷衍生物的结晶及其制备方法 Pending CN105612159A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010091853.6A CN111153903A (zh) 2013-10-08 2014-10-08 二氮杂二环辛烷衍生物的结晶及其制备方法和应用以及医药组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013211242 2013-10-08
JP2013-211242 2013-10-08
PCT/JP2014/076875 WO2015053297A1 (ja) 2013-10-08 2014-10-08 ジアザビシクロオクタン誘導体の結晶とその製造法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010091853.6A Division CN111153903A (zh) 2013-10-08 2014-10-08 二氮杂二环辛烷衍生物的结晶及其制备方法和应用以及医药组合物

Publications (1)

Publication Number Publication Date
CN105612159A true CN105612159A (zh) 2016-05-25

Family

ID=52813113

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480055342.1A Pending CN105612159A (zh) 2013-10-08 2014-10-08 二氮杂二环辛烷衍生物的结晶及其制备方法
CN202010091853.6A Pending CN111153903A (zh) 2013-10-08 2014-10-08 二氮杂二环辛烷衍生物的结晶及其制备方法和应用以及医药组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010091853.6A Pending CN111153903A (zh) 2013-10-08 2014-10-08 二氮杂二环辛烷衍生物的结晶及其制备方法和应用以及医药组合物

Country Status (22)

Country Link
US (5) US10131665B2 (cg-RX-API-DMAC7.html)
EP (4) EP3613740A1 (cg-RX-API-DMAC7.html)
JP (3) JP6617029B2 (cg-RX-API-DMAC7.html)
KR (2) KR102388529B1 (cg-RX-API-DMAC7.html)
CN (2) CN105612159A (cg-RX-API-DMAC7.html)
AR (4) AR097971A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014332960B2 (cg-RX-API-DMAC7.html)
BR (2) BR122022016622B1 (cg-RX-API-DMAC7.html)
CA (2) CA3110803C (cg-RX-API-DMAC7.html)
DK (1) DK3067355T3 (cg-RX-API-DMAC7.html)
ES (2) ES2901198T3 (cg-RX-API-DMAC7.html)
HK (1) HK1219479A1 (cg-RX-API-DMAC7.html)
HU (1) HUE051925T2 (cg-RX-API-DMAC7.html)
IL (2) IL244969B (cg-RX-API-DMAC7.html)
MX (2) MX383661B (cg-RX-API-DMAC7.html)
MY (1) MY199066A (cg-RX-API-DMAC7.html)
NZ (5) NZ719568A (cg-RX-API-DMAC7.html)
RU (1) RU2695219C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201602723RA (cg-RX-API-DMAC7.html)
TW (1) TWI673269B (cg-RX-API-DMAC7.html)
WO (1) WO2015053297A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201602054B (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107941944A (zh) * 2017-11-23 2018-04-20 中山奕安泰医药科技有限公司 一种(2s,5r)‑苄氧胺基哌啶‑2‑甲酸乙酯草酸盐的检测方法
CN107991404A (zh) * 2017-11-23 2018-05-04 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酰胺的检测方法
CN111447924A (zh) * 2017-09-27 2020-07-24 费多拉制药公司 二氮杂二环辛烷衍生物的药物形式及其制备方法
CN111448195A (zh) * 2017-09-27 2020-07-24 费多拉制药公司 二氮杂二环辛烷衍生物的晶型及其生产方法
CN111465604A (zh) * 2017-09-27 2020-07-28 费多拉制药公司 二氮杂二环辛烷衍生物的药物形式及其制备方法
CN112930338A (zh) * 2018-09-21 2021-06-08 株式会社Api 氨基酸衍生物的制备方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
DK3050883T3 (da) * 2013-09-24 2020-05-25 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
CN105612159A (zh) 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法
SG11201704576SA (en) * 2014-12-05 2017-07-28 Meiji Seika Pharma Co Ltd Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
US10208041B2 (en) * 2016-10-07 2019-02-19 Hoffman-La Roche Inc. Diazabicyclooctane compounds
KR20200030584A (ko) 2017-07-21 2020-03-20 앤타바이오 에스에이에스 화합물
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
WO2022014395A1 (ja) * 2020-07-13 2022-01-20 日本碍子株式会社 精製方法
CN113552250A (zh) * 2021-06-30 2021-10-26 海南海灵化学制药有限公司 一种盐酸头孢唑兰的杂质检测方法
WO2024263708A2 (en) * 2023-06-23 2024-12-26 Board Of Trustees Of Michigan State University Ornithine decarboxylase (odc) inhibitors and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010126820A2 (en) * 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
JP2011207900A (ja) * 2008-01-18 2011-10-20 Merck Sharp & Dohme Corp β−ラクタマーゼ阻害剤
WO2012172368A1 (en) * 2011-06-17 2012-12-20 Astrazeneca Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
US20130225554A1 (en) * 2011-12-02 2013-08-29 Naeja Pharmaceutical Inc. New bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5038509B1 (cg-RX-API-DMAC7.html) 1970-10-21 1975-12-10
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用11115152139199東京都中央区京橋2丁目3番13号
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (cg-RX-API-DMAC7.html) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶,該結晶を含む凍結乾燥製剤,およびその製造方法
US6111098A (en) 1994-05-02 2000-08-29 Shionogi & Co., Ltd. Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same
DE19531874C1 (de) 1995-08-30 1996-10-02 Daimler Benz Ag Seitenwandbaugruppe für eine Kraftfahrzeugkarosserie
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP2012122603A (ja) * 2010-11-15 2012-06-28 Nifco Inc コネクタ装置
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
SI2657234T1 (sl) 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo
BR112013028813B1 (pt) 2011-08-27 2020-10-20 Wockhardt Limited derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem
CN103649088B (zh) 2011-08-30 2016-05-11 沃克哈特有限公司 1, 6- 二氮杂双环[3, 2, 1]辛- 7- 酮衍生物及其在治疗细菌感染中的用途
BR112014003476A2 (pt) 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
ES2672100T3 (es) * 2012-08-25 2018-06-12 Wockhardt Limited Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona y su uso en el tratamiento de infecciones bacterianas
DK3050883T3 (da) * 2013-09-24 2020-05-25 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
CN105612159A (zh) 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法
IN2014MU01192A (cg-RX-API-DMAC7.html) 2014-03-29 2015-10-02 Wockhardt Ltd
SG11201704576SA (en) 2014-12-05 2017-07-28 Meiji Seika Pharma Co Ltd Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011207900A (ja) * 2008-01-18 2011-10-20 Merck Sharp & Dohme Corp β−ラクタマーゼ阻害剤
WO2010126820A2 (en) * 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
WO2012172368A1 (en) * 2011-06-17 2012-12-20 Astrazeneca Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
US20130225554A1 (en) * 2011-12-02 2013-08-29 Naeja Pharmaceutical Inc. New bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111447924A (zh) * 2017-09-27 2020-07-24 费多拉制药公司 二氮杂二环辛烷衍生物的药物形式及其制备方法
CN111448195A (zh) * 2017-09-27 2020-07-24 费多拉制药公司 二氮杂二环辛烷衍生物的晶型及其生产方法
CN111465604A (zh) * 2017-09-27 2020-07-28 费多拉制药公司 二氮杂二环辛烷衍生物的药物形式及其制备方法
CN111465604B (zh) * 2017-09-27 2023-05-12 明治制果药业株式会社 二氮杂二环辛烷衍生物的药物形式及其制备方法
CN107941944A (zh) * 2017-11-23 2018-04-20 中山奕安泰医药科技有限公司 一种(2s,5r)‑苄氧胺基哌啶‑2‑甲酸乙酯草酸盐的检测方法
CN107991404A (zh) * 2017-11-23 2018-05-04 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酰胺的检测方法
CN107941944B (zh) * 2017-11-23 2020-09-15 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法
CN107991404B (zh) * 2017-11-23 2021-01-08 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酰胺的检测方法
CN112930338A (zh) * 2018-09-21 2021-06-08 株式会社Api 氨基酸衍生物的制备方法

Also Published As

Publication number Publication date
CA2926071A1 (en) 2015-04-16
RU2016116501A (ru) 2017-11-15
EP3067355A1 (en) 2016-09-14
HK1219479A1 (zh) 2017-04-07
ZA201602054B (en) 2019-06-26
US20220348578A1 (en) 2022-11-03
CA3110803C (en) 2022-09-27
CA2926071C (en) 2021-11-09
AU2014332960B2 (en) 2018-03-29
WO2015053297A1 (ja) 2015-04-16
JP6995810B2 (ja) 2022-01-17
NZ757222A (en) 2021-12-24
MX361659B (es) 2018-12-13
EP3613740A1 (en) 2020-02-26
IL244969A0 (en) 2016-05-31
KR102388529B1 (ko) 2022-04-20
JP7182677B2 (ja) 2022-12-02
US20200181143A1 (en) 2020-06-11
US20250059191A1 (en) 2025-02-20
US12221443B2 (en) 2025-02-11
EP3299370B1 (en) 2021-11-24
EP3299370A1 (en) 2018-03-28
SG11201602723RA (en) 2016-05-30
IL289275B2 (en) 2023-02-01
AU2014332960A1 (en) 2016-05-26
US10604522B2 (en) 2020-03-31
ES2901198T3 (es) 2022-03-21
JP2021193107A (ja) 2021-12-23
EP3067355B1 (en) 2020-12-16
IL289275B (en) 2022-10-01
NZ743374A (en) 2021-12-24
MX383661B (es) 2025-03-14
TW201605855A (zh) 2016-02-16
KR20160065871A (ko) 2016-06-09
NZ719568A (en) 2018-06-29
US20190031659A1 (en) 2019-01-31
RU2695219C2 (ru) 2019-07-22
EP3067355A4 (en) 2017-04-26
RU2016116501A3 (cg-RX-API-DMAC7.html) 2018-07-12
DK3067355T3 (da) 2021-01-04
CA3110803A1 (en) 2015-04-16
MY199066A (en) 2023-10-12
CN111153903A (zh) 2020-05-15
US10131665B2 (en) 2018-11-20
AR132030A2 (es) 2025-05-21
MX2016004506A (es) 2016-06-16
AR097971A1 (es) 2016-04-20
US20160272641A1 (en) 2016-09-22
JPWO2015053297A1 (ja) 2017-03-09
AR132029A2 (es) 2025-05-21
HUE051925T2 (hu) 2021-04-28
EP3613741A1 (en) 2020-02-26
IL289275A (en) 2022-02-01
BR112016006266A2 (cg-RX-API-DMAC7.html) 2017-08-22
BR122022016622B1 (pt) 2023-11-07
HK1250030A1 (en) 2018-11-23
KR20220054694A (ko) 2022-05-03
KR102487297B1 (ko) 2023-01-12
US11414417B2 (en) 2022-08-16
JP2020007366A (ja) 2020-01-16
NZ757220A (en) 2021-12-24
AR132028A2 (es) 2025-05-21
NZ757221A (en) 2021-12-24
RU2019115119A3 (cg-RX-API-DMAC7.html) 2022-04-26
RU2019115119A (ru) 2019-05-29
BR112016006266B1 (pt) 2022-11-16
TWI673269B (zh) 2019-10-01
JP6617029B2 (ja) 2019-12-04
ES2842225T3 (es) 2021-07-13
IL244969B (en) 2022-01-01

Similar Documents

Publication Publication Date Title
JP7182677B2 (ja) ジアザビシクロオクタン誘導体の結晶とその製造法
RU2838718C2 (ru) Кристаллические формы производного диазабициклооктана и способ их получения
RU2840014C2 (ru) Кристаллические формы производного диазабициклооктана и способ их получения
RU2847390C2 (ru) Кристаллические формы производного диазабициклооктана и способ их получения
RU2801220C2 (ru) Кристаллические формы производного диазабициклооктана и способ их получения
HK40027891A (zh) 二氮杂二环辛烷衍生物的结晶及其制备方法和应用以及医药组合物
HK40023145A (en) Preparation of a diazabicyclooctane derivative
HK40023146A (en) Preparation of a diazabicyclooctane derivative
HK1226731A1 (en) Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
HK1226731B (en) Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1219479

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20160525

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1219479

Country of ref document: HK